Spots Global Cancer Trial Database for advanced cervical cancer
Every month we try and update this database with for advanced cervical cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer | NCT05521997 | Advanced Cervic... Cervical Cancer Cervix Cancer Cancer of the C... | Telaglenastat Radiation treat... Cisplatin | 18 Years - | Washington University School of Medicine | |
| Study of ADXS11-001 in Participants With High Risk Locally Advanced Cervical Cancer | NCT02853604 | High Risk Cervi... Advanced Cervic... | ADXS11-001 Placebo | 18 Years - | Advaxis, Inc. | |
| Advanced Cervical Cancer Trial in India | NCT01276730 | Cervical Cancer | Interferon, Ret... Cisplatin and r... | 18 Years - | University of Louisville | |
| Dostarlimab and Cobolimab in Advanced Cervical Cancer | NCT06238635 | Cervical Cancer Advanced Cervic... Metastatic Cerv... Metastatic Cerv... Recurrent Cervi... | Dostarlimab Cobolimab | 18 Years - | Beth Israel Deaconess Medical Center | |
| Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 1) | NCT04508686 | Advanced Cervic... | Capecitabine, c... | 18 Years - | Ruijin Hospital | |
| Mapatumumab, Cisplatin and Radiotherapy for Advanced Cervical Cancer | NCT01088347 | Advanced Cervic... | mapatumumab cisplatin radiotherapy | 18 Years - 99 Years | University Medical Center Groningen | |
| Dostarlimab and Cobolimab in Advanced Cervical Cancer | NCT06238635 | Cervical Cancer Advanced Cervic... Metastatic Cerv... Metastatic Cerv... Recurrent Cervi... | Dostarlimab Cobolimab | 18 Years - | Beth Israel Deaconess Medical Center | |
| Study of ADXS11-001 in Participants With High Risk Locally Advanced Cervical Cancer | NCT02853604 | High Risk Cervi... Advanced Cervic... | ADXS11-001 Placebo | 18 Years - | Advaxis, Inc. | |
| Study of ADXS11-001 in Participants With High Risk Locally Advanced Cervical Cancer | NCT02853604 | High Risk Cervi... Advanced Cervic... | ADXS11-001 Placebo | 18 Years - | Advaxis, Inc. | |
| A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based Chemotherapy | NCT04590599 | Advanced Cervic... | IBI310 Placebo Sintilimab | 18 Years - 75 Years | Innovent Biologics (Suzhou) Co. Ltd. | |
| Chemotherapy With Anlotinib in Advanced Cervical Cancer | NCT04695535 | Uterine Cervica... | 18 Years - | Zhongda Hospital | ||
| Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 1) | NCT04508686 | Advanced Cervic... | Capecitabine, c... | 18 Years - | Ruijin Hospital | |
| Chemotherapy With Anlotinib in Advanced Cervical Cancer | NCT04695535 | Uterine Cervica... | 18 Years - | Zhongda Hospital | ||
| Study of Velcade and Irinotecan in Advanced Cervical, Vulvar, or Vaginal Cancer | NCT00106262 | Cervical Cancer | Velcade (bortez... Irinotecan | 18 Years - 80 Years | Women and Infants Hospital of Rhode Island | |
| Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046) | NCT04551950 | Cervical Cancer | M7824 Carboplatin Paclitaxel Bevacizumab Cisplatin Radiotherapy | 18 Years - | EMD Serono | |
| Molecular Biology Analysis for Para-aortic Nodes in the Ultra-staging of Advanced Cervical Cancers | NCT02888717 | Advanced Cervic... | 'OSNA stadifica... | 18 Years - | Institut Cancerologie de l'Ouest |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
